What Patients Need to Know About Early-Stage and Metastatic Breast Cancer The 2026 NCCN breast cancer guideline update shows that breast cancer care is becoming more personalized. But the most important thing for patients to understand is that the changes are not the same for everyone. For some people with early-stage breast cancer, the update […]
2026 Breast Cancer Guideline Update Read More »
August delivered a compact but meaningful set of oncology updates: two U.S. FDA accelerated approvals and several practice-informing papers across skin, lung, head & neck, kidney, colorectal, breast, and hematologic cancers. Lung cancer 1) HER2-mutant NSCLC — zongertinib wins FDA accelerated approval 2) KRAS G12C NSCLC — adagrasib bests docetaxel in phase 3 (KRYSTAL-12) Brain
Cancer breakthroughs & approvals in August 2025 Read More »
This collection highlights real stories of triple-negative breast cancer patients who achieved long-term survival through multiple lines of treatment—options often not fully detailed in standard guidelines
CASE SELECTION 4: Long-Term Survival with Stage 4 HER2-Positive Breast Cancer Read More »
A cancer diagnosis can feel overwhelming, stripping away a sense of control. Yet experts urge patients and caregivers to focus on what you can control. In other words, find the “CAN” in your cancer journey – the things you can do, even when many factors remain beyond your control. This article explores practical areas where you do have power
Finding the “CAN” in Cancer: Empowerment and Action Read More »
The FDA has just approved zongertinib (brand name Hernexeos) – a new targeted pill – for adults with advanced non-small cell lung cancer (NSCLC) that carries a specific HER2 gene mutation.
Zongertinib: A New Hope for HER2-Mutant Lung Cancer Read More »
Modern chemotherapy is much kinder than its reputation. Thanks to advances in medicine and supportive care, many side effects have improved significantly, allowing patients to maintain a near-normal life during treatment. This article explores how chemo side effects have become far more manageable, backed by data and patient experiences, and offers tips for living well through therapy.
Kinder Chemotherapy Side Effects: Two Decades of Gradual Improvement Read More »
Following are key take‑home messages from ESMO GI 2025 (Barcelona, 2–5 July), organized by cancer type.
Highlights From ESMO Gastrointestinal Cancers Congress 2025 Read More »
New treatments and smarter strategies are transforming what was once a nearly hopeless scenario into one with genuine hope and possibility. Today, experts urge patients not to be discouraged by outdated averages, because outcomes are improving every year and can vary widely depending on individual factors.
A Decade of Progress: Rising 5-Year Survival in Stage IV Gastric Cancer Read More »
Not long ago, a diagnosis of stage IV colon cancer – cancer that has spread to distant organs – was often seen as a dire situation. Historically, five-year survival rates were in the low double digits, and many patients felt they were facing insurmountable odds. But today, we are witnessing a new era of hope. In the last decade, survival statistics have significantly improved, and more patients are defying the old expectations.
Stage IV Colon Cancer Survival: A Decade of Dramatic Improvement and Hope Read More »
Stage IV lung cancer was once considered almost hopeless, with very few patients surviving five years. But in the last decade, new treatments have significantly improved those odds. Today, more stage IV lung cancer patients are living longer – some well beyond five years – thanks to breakthroughs like targeted therapies and immunotherapy. This article
Advanced Lung Cancer: Dramatic Improvements in 5-Year Survival Offer New Hope Read More »
